Omburtamab I-131
- Generic Name
- Omburtamab I-131
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- B6PMV8U3C4
- Associated Conditions
- -
- Associated Therapies
- -
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT05063357
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT05064306
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 62
- Registration Number
- NCT04743661
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT04022213
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath